结直肠癌单克隆抗体靶向治疗探讨
被引量：1
Investigation treatment of colorectal cancer monoclonal antibodies
摘要
近年来,靶向药物的出现改善了结直肠癌患者的治疗预期,其与化疗药物的联合应用提高了化疗的疗效,进一步延长了患者的生存期。随着分子靶向药物治疗相关研究的深入,靶向药物已成为结直肠癌个体化治疗和综合治疗的新选择。
出处
《中国医学前沿杂志（电子版）》
2010年第2期11-15,共5页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
参考文献21
-
1Hurwitz H;Fehrenbacher L;Novotny W.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer[J],2004(23).
-
2Fuchs CS;Marshall J;Mitchell E.Randomized,controlled trial of irinotecan plus infusional,bolus,or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer:results from the BICC-C study[J]Journal of Clinical Oncology,2007(30):4779-4786.
-
3Hochster HS;Hart LL;Ramanathan RK.Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer:results of the TREE study[J]Journal of Clinical Oncology,2008(21):3523-3529.
-
4Saltz L;Clarke S;Diaz-Rubio E.Bevacizumab in combination with XELOX or FOLFOX-4:updated efficacy results from XELOX-1/NO16966,a randomized phase III trial in first-line metastatic colorectal cancer[J]Journal of Clinical Oncology,2007(18):4028.
-
5Cassidy J;Clarke S;Diaz-Rubio E.XELOX-1/NO16966,a randomized phase III trial of first-line XELOX compared with FOLFOX4 for patients with metastatic colorectal cancer (MCRC):Updated survival and tolerability results[A].
-
6Giantonio BJ;Catalano PJ;Meropol NJ.Bevacizumab in combination with oxaliplatin,fluorouracil,and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200[J]Journal of Clinical Oncology,2007(12):1539-1544.
-
7Derek J;Chris J;Christos S.Cetuximab for the treatment of colorectal cancer[J]New England Journal of Medicine,2007(20):2040-2048.
-
8Cunningham D;Humblet Y;Siena S.Cetuximab monotherapy and cetuximab plus irinotecan in irinotecanrefractory metastatic colorectal cancer[J]New England Journal of Medicine,2004(04):337-345.
-
9Bokemeyer C;Bondarenko I;Makhson A.Fluorouracil,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer[J]Journal of Clinical Oncology,2009(05):663-671.
-
10Van Cutsem E;Kōhne C;Hitre E.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J]New England Journal of Medicine,2009(14):1408-1417.
共引文献5
-
1詹天成,李明,顾晋.临床多学科合作模式治疗直肠癌肝转移—实例报道[J].中国医学前沿杂志（电子版）,2010,2(4):66-69.
-
2钟芸诗,许剑民.结直肠癌肝转移的综合治疗[J].中国继续医学教育,2011,3(9):43-47. 被引量：2
-
3刘欣,王宝成.结直肠癌靶向治疗研究进展[J].实用医药杂志,2013,30(12):1125-1128.
-
4徐建波,何裕隆,吴晖,彭建军,张信华,张常华,蔡世荣,詹文华.结直肠癌同时性肝转移的预后因素分析[J].消化肿瘤杂志（电子版）,2011,3(2):100-104. 被引量：2
-
5李连勇,刘庆森.结直肠癌辅助化疗演进及新进展[J].实用医技杂志,2006,13(6):962-964. 被引量：1
二级引证文献4
-
1王上游,米雄飞.托里消毒散结合卡介菌多糖核酸注射液治疗尖锐湿疣的临床研究[J].中医药导报,2017,23(3):85-88. 被引量：5
-
2于霞,蒋丽丽,朱卫华.康艾注射液联合FOLFOX化疗方案治疗结直肠癌的临床研究[J].癌症进展,2018,16(5):650-653. 被引量：13
-
3沈莹,高啸,谭晓燕.抗人VEGFR2与抗人EGFR的双特异性重组蛋白治疗结直肠癌的体内外研究[J].解剖学研究,2018,40(4):248-252. 被引量：3
-
4于晓洁,丘木水(综述),宋佳星(审校).CD4^(+)和CD8^(+)T淋巴细胞在结直肠癌诊治中的临床应用[J].检验医学与临床,2021,18(18):2758-2762. 被引量：12
-
1宋磊,田晓勤,冯仲珉.乌体林斯、白介-Ⅱ联合应用提高肿瘤患者免疫水平的临床观察[J].实用药物与临床,2002,6(S1):21-21.
-
2李德昌,任力,李桢,毛志远.45例胃肠道间质瘤的临床病理及免疫组化分析[J].内蒙古中医药,2008,27(8X):6-8.
-
3王誉雅,江舟.原发性肝细胞癌肿瘤标志物及药物靶点的研究进展[J].华西医学,2014,29(8):1579-1582.
-
4盛莉莉,吉兆宁.大肠癌的分子靶向治疗[J].中国临床药理学与治疗学,2013,18(6):715-720. 被引量：2
-
5陈刚,赵士彭,赵志芳,段惠军.塞来昔布联合奥沙利铂对人肺癌裸鼠移植瘤的治疗作用及其作用机制的研究[J].中国肿瘤临床,2008,35(1):49-53. 被引量：6
-
6朱建新,张艾莉,李然春,闫于悌.双吻合器在直肠癌保肛手术中的应用（附246例报告）[J].中国肛肠病杂志,2003,23(10):30-32.
-
7倪才方,刘一之,邵国良,朱晓黎,丁乙,陈学仁.DSA在肝癌诊断和介入治疗中的应用[J].苏州医学院学报,1998,18(8):872-873. 被引量：1
-
8刘艳平,彭开桂,李多杰.原发性食管小细胞癌的诊治进展[J].蚌埠医学院学报,2012,37(11):1390-1392. 被引量：3
-
9徐敏毅,林晨,梁萧,付明,张雪艳,吴旻.基因治疗与化疗联合应用对人肺腺癌GLC-82细胞作用的实验研究[J].中华医学杂志,2000,80(9):689-693. 被引量：4
-
10郎哲,陈刚,王东昌.尼美舒利联合奥沙利铂对人肺癌裸鼠移植瘤生长及淋巴转移的抑制作用[J].中华肿瘤杂志,2012,34(10):739-744. 被引量：10
